Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

75199

Sigma-Aldrich

Azithromycin

Sinonimo/i:

CP 62,993

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C38H72N2O12
Numero CAS:
83905-01-5
Peso molecolare:
748.98
Numero MDL:
MFCD00873574
Codice UNSPSC:
12352200
ID PubChem:
329766256
NACRES:
NA.77

Forma fisica

powder

Livello qualitativo

200

Attività ottica

[α]/D −45±2°, c = 1% in ethanol

Spettro attività antibiotica

viruses

applicazioni

environmental

Modalità d’azione

protein synthesis | interferes

Stringa SMILE

CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O

InChI

1S/C38H72N2O12/c1-15-27-38(10,46)31(42)24(6)40(13)19-20(2)17-36(8,45)33(52-35-29(41)26(39(11)12)16-21(3)48-35)22(4)30(23(5)34(44)50-27)51-28-18-37(9,47-14)32(43)25(7)49-28/h20-33,35,41-43,45-46H,15-19H2,1-14H3/t20-,21-,22+,23-,24-,25+,26+,27-,28+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1
MQTOSJVFKKJCRP-BICOPXKESA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

Azithromycin is a hydrophobic azalide and a derivative of erythromycin. It belongs to the macrolide class of antibodies.

Applicazioni

Azithromycin has been used:

  • to treat synchronized Plasmodium falciparum Dd2 parasites for continuous growth assays to study the antiparasitic mechanisms of doxycycline (DOX)
  • to study its bactericidal activity against Pseudomonas aeruginosa in combination with a recombinant hemolymph plasma lectin (rHPLOE)
  • in evolution experiments to study P. aeruginosa strain PA14’s response to bacteriostatic antibiotics

Azioni biochim/fisiol

Azithromycin is a broad-spectrum antimicrobial agent, effective against infections associated with respiratory tract, skin, tissues, and genital chlamydia. It acts against Gram-negative bacteria (including Enterobacteriaceae) and several Gram-positive organisms. It also acts against Plasmodium falciparum and P. vivax, which are multidrug resistance species that transmit malaria. Azithromycin targets the plasmodial ribosome and prevents protein synthesis. It is soluble in lipids and metabolizes in the liver by undergoing demethylation. It is commonly used to treat community-acquired pneumonia, sexually transmitted diseases, acute otitis media, and acute exacerbation of chronic obstructive pulmonary disease (COPD).

Caratteristiche e vantaggi

  • Rapidly absorbed
  • Shows great tissue penetration and procures high intracellular concentration
  • Distributes widely in body fluids and tissues

Confezionamento

Bottomless glass bottle. Contents are inside inserted fused cone.

Pittogrammi

Health hazardEnvironment
GHS08,GHS09

Avvertenze

Danger

Indicazioni di pericolo

H317,H334,H410

Classi di pericolo

Aquatic Chronic 1 - Resp. Sens. 1 - Skin Sens. 1

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Faceshields, Gloves, type N95 (US)

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 8

1 of 8

Azaserine Hybri-Max™, γ-irradiated, 50x, lyophilized powder, BioXtra, suitable for hybridoma

Sigma-Aldrich

A1164

Azaserine

Telithromycin ≥90% (HPLC)

Sigma-Aldrich

SML2162

Telithromycin

Azaserine ≥98% (TLC)

Sigma-Aldrich

A4142

Azaserine

Clarithromycin European Pharmacopoeia (EP) Reference Standard

Y0000320

Clarithromycin

USP

USP

1046090

Azithromycin N-oxide

Clarithromycin 96.0-102.0% (HPLC)

Sigma-Aldrich

A3487

Clarithromycin

Ciprofloxacin ≥98% (HPLC)

Sigma-Aldrich

17850

Ciprofloxacin

Fidaxomicin ≥95% (HPLC)

Sigma-Aldrich

SML1750

Fidaxomicin

Leonard B Bacharier et al.
JAMA, 314(19), 2034-2044 (2015-11-18)
Many preschool children develop recurrent, severe episodes of lower respiratory tract illness (LRTI). Although viral infections are often present, bacteria may also contribute to illness pathogenesis. Strategies that effectively attenuate such episodes are needed. To evaluate if early administration of
Hanna Retallack et al.
Proceedings of the National Academy of Sciences of the United States of America, 113(50), 14408-14413 (2016-12-03)
The rapid spread of Zika virus (ZIKV) and its association with abnormal brain development constitute a global health emergency. Congenital ZIKV infection produces a range of mild to severe pathologies, including microcephaly. To understand the pathophysiology of ZIKV infection, we
Chris S Earl et al.
EMBO molecular medicine, 7(8), 1018-1033 (2015-05-23)
Glucocorticosteroids are used as a main treatment to reduce airway inflammation in people with asthma who suffer from neutrophilic airway inflammation, a condition frequently associated with Haemophilus influenzae colonization. Here we show that glucocorticosteroids have a direct influence on the
Alison M Binder et al.
American journal of respiratory and critical care medicine, 188(7), 807-812 (2013-08-10)
Persons with cystic fibrosis (CF) are at high risk of nontuberculous mycobacterial (NTM) infection, with treatment requiring prolonged multidrug regimens that include macrolides. Although macrolides, specifically azithromycin, are used in the management of patients with CF with chronic Pseudomonas, macrolide-resistant
Patricia C Valery et al.
The Lancet. Respiratory medicine, 1(8), 610-620 (2014-01-28)
Indigenous children in high-income countries have a heavy burden of bronchiectasis unrelated to cystic fibrosis. We aimed to establish whether long-term azithromycin reduced pulmonary exacerbations in Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease. Between Nov 12, 2008
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.